Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers with the Metabolic Inhibitor Ranolazine

 


A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers with the Metabolic Inhibitor Ranolazine


Trial Focus

Prostate Cancer

Objective

         This study plans to learn more about whether taking a drug called ranolazine will help improve the ability to detect prostate cancers by PET scans.

IRB Protocol #

13-1908

Trial Status

OPEN

Principle Investigator

ELAINE LAM

Sponsor

UCCC

Contact

MICHAEL WACKER at (720)848-3427 or MICHAEL.WACKER@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. You will be asked to take 1 ranolazine pill twice a day for 5 days, then you will undergo a second PET/CT scan on the day after your complete your 5 days of ranolazine treatment. This scan will help determine whether more of your prostate cancer can be seen after receiving ranolazine. // Eligibility criteria include but are not limited to 18 years or older with prostate cancer.Eligibility criteria include but are not limited to 18 years or older with prostate cancer.